Cigna · Anti Cd 20 Ocrevus · US health-plan appeal rights

Anti Cd 20 Ocrevus denied for failing step therapy by Cigna?

Q: How long do I have to appeal a Cigna Anti Cd 20 Ocrevus denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Cigna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Cigna Drug coverage policy - Ocrevus / ocrelizumab; Multiple Sclerosis Agents PA criteria

The Cigna angle on Anti Cd 20 Ocrevus

## Why Cigna Uses Step Therapy for Ocrelizumab

Step therapy — sometimes called "fail first" — is Cigna's requirement that patients try one or more other disease-modifying therapies (DMTs) before ocrelizumab (Ocrevus) will be covered. This is among the most common denial types for high-efficacy MS therapies. Cigna's clinical policy designates certain lower-cost or lower-efficacy agents as required first steps, and coverage of ocrelizumab is conditioned on documented failure of, intolerance to, or contraindication against those agents.

## Why This Denial Is Appealable

Step-therapy protocols are not unconditional. Federal law and most state step-therapy reform statutes require insurers to grant an exception when: (1) the required prior therapy is contraindicated or likely to cause harm; (2) the patient already tried and failed the required agent; or (3) the required step would delay treatment of a serious or life-threatening condition. Many states have enacted step-therapy exception laws that impose strict timelines on insurers. If any exception ground applies, Cigna must cover ocrelizumab without requiring you to restart a therapy you have already tried.

## Your Federal Appeal Rights

Internal appeal: ERISA §503 and ACA §2719 guarantee a full-and-fair review. Check your denial letter for the filing deadline.
External review: After exhausting internal remedies, an independent external review is available under ACA §2719, generally within approximately four months of final internal denial.
Expedited track: Patients with rapidly progressing disease or who are mid-treatment should request expedited review; decisions are typically required within 72 hours.
State protections: Many states have step-therapy exception statutes with their own timelines and insurer obligations. Check whether your state's law applies to your plan type.

## Documentation to Gather

1. Prior DMT history — a dated list of every disease-modifying therapy you have tried, with start dates, stop dates, and specific reasons for stopping (adverse effect, lack of efficacy, contraindication). 2. Clinical notes documenting failure or intolerance — chart entries, adverse-event records, or lab results that substantiate each prior treatment outcome. 3. Neurologist's medical-necessity letter explaining why ocrelizumab is clinically appropriate and why the required step-therapy agents are not suitable for your specific case. 4. Cigna's step-therapy policy — obtain the written policy to identify exactly which agents are required steps and what exception criteria Cigna accepts. 5. Diagnosis and disease-activity records — MRI reports, relapse history, and disability assessments that establish clinical urgency if applicable.

## Criteria-Mapping Approach

List each step-therapy requirement from Cigna's policy in the left column of a table. In the right column, document precisely how your history satisfies or provides an exception to each requirement — citing the chart date, drug name, and outcome. If your neurologist is recommending ocrelizumab as initial high-efficacy therapy based on disease characteristics, the letter should explain that clinical rationale explicitly, referencing the applicable guideline organization (such as the relevant neurology society guidelines) without needing to quote specific statistics.

## Next Step

Obtain Cigna's written step-therapy policy before drafting the appeal. Confirm which specific agents are listed as required steps and cross-reference your treatment history against that list. If you have already tried any of them, the documentation package above should be sufficient to establish exception eligibility.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on Anti Cd 20 Ocrevus

Other denial reasons for Cigna Anti Cd 20 Ocrevus

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.